Phase 2 biomarker study to evaluate CTX-009 in DLL4-positive colorectal cancer
Latest Information Update: 14 Jan 2025
Price :
$35 *
At a glance
- Drugs CTX 009 (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 14 Jan 2025 New trial record
- 08 Jan 2025 According to Compass Therapeutics media release, this Phase 2 biomarker trial is expected to initiate in mid-2025.